Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D018579:Patient Selection; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077285:Rimonabant; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant